论文部分内容阅读
利用血卟啉衍生物(HpD)的光敏反应治疗恶性肿瘤,国外早已有报道。国内1980年北京首先开展HpD的研究工作。我所和中国科学院上海生化研究所协作,于1983年初开展HpD的抗肿瘤实验性研究。据报道静脉注射HpD后,在一般组织中代谢较快,而在肿瘤组织中则较慢,49～96小时肿瘤组织的浓度比一般组织高2～10倍。由于本品系光敏化剂,在一定波长的激光照射激发下可产生单态氧,杀伤肿瘤细胞,以达到治疗的目的。据此设计了本实验性治疗试验。
The use of photosensitizing reactions of hematoporphyrin derivatives (HpD) to treat malignant tumors has long been reported abroad. In 1980, Beijing first launched research on HpD. In collaboration with the Shanghai Institute of Biochemistry of the Chinese Academy of Sciences, the Institute conducted an anti-tumor experimental study of HpD in early 1983. It has been reported that after HpD is injected intravenously, the metabolism is faster in general tissues and slower in tumor tissues, and the concentration of tumor tissues is 2 to 10 times higher than that of normal tissues in 49 to 96 hours. Because this product is a photosensitizer, single-state oxygen can be generated under the excitation of a certain wavelength of laser irradiation to kill tumor cells for therapeutic purposes. Based on this, this experimental treatment trial was designed.